Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Luckin Coffee (LKNCY US)
Watchlist
276
Analysis
Consumer Discretionary
•
China
Luckin Coffee Inc. provides non-alcoholic beverages. The Company offers various types of coffee. Luckin Coffee serves customers in China.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
13 Jun 2024 18:04
[Blue Lotus Daily]:1211 HK/300750 SZ/BEKE US/LKNCY US
Geely and SK Group deepen cooperation in batteries, PBoC urges affordable housing re-lending, Luckin expands non-coffee drinks with lemonade sales.
Blue Lotus Research Institute
Follow
126 Views
Share
bearish
•
Thematic (Sector/Industry)
•
11 Jun 2024 19:00
How to Stimulate China's Consumption? Part I
The myth of China underconsumption depends on how you count it. China under-consumes in certain consumption categories associated with an older and...
Blue Lotus Research Institute
Follow
443 Views
Share
bullish
•
Thematic (Sector/Industry)
•
17 May 2024 10:26
[Blue Lotus Daily]:1810 HK/ZK US/NIO US/TSLA US/XPEV US/600104 SH/1211 HK/ LI US/LKNCY US
Xiaomi to start double-shift production of SU7, FSD12 users conversion rate low, Li Auto leads in sales in 18th week of 2024.
Blue Lotus Research Institute
Follow
459 Views
Share
bullish
•
Thematic (Sector/Industry)
•
24 Apr 2024 15:51
[Blue Lotus Daily]:1810HK/LI US/LKNCY US/AAPL/TSM/1810 HK
Tesla cuts prices of all series to compete with XiaomiSU7 and LI L6.Huawei launches new flagship featuring upgrading processors.LI cuts price,...
Blue Lotus Research Institute
Follow
296 Views
Share
bullish
•
Thematic (Sector/Industry)
•
10 Apr 2024 16:46
[Blue Lotus Daily]:XPEV/1211 HK/3759HK/1548HK/9926HK/BGNE/9995HK/1801 HK/1810HK/LKNCY/LI/NIO/MNSO US
Didi and GAC Aion to launch first commercial L4 model in 2025, US biologic drug ban could benefit Chinese innovative drug companies, Xiaomi SU7...
Blue Lotus Research Institute
Follow
406 Views
Share
First
Previous
6
7
8
9
10
11
12
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x